Tripla negatív emlőrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-L1 26
• HER2 24
• PD-1 36
• BRCA1 5
• STAT3 1
• STING 0
• EGFR 4
• PI3K 1
• AKT 0
• BRCA2 2
• TP53 1
• PARP 1
• mTOR 0
• TROP2 6
• AR 1
• PTEN 0
• VEGF 4
• CDK4/6 3
• HIF-1 0
• MYC 0
• GPX4 0
• YAP 0
• CTNNB1 0
• JAK 1
• HDAC 0
• MAPK 0
• BCL-2 0
• CXCR4 1
• ERK 0
• NRF2 0
• PPAR 0
• B7-H3 4
• EZH2 0
• FAK 0
• PRMT5 0
• CD47 0
• HSP90 0
• PSMA 4
• IL-6 0
• PIK3CA 2
• CTLA-4 1
• HER3 2
• TNF 0
• COX-2 0
• IGF1R 0
• MEK 0
• FGFR 0
• MDM2 2
• MET 0
• MUC1 3
• NLRP3 0
• PALB2 0
• AMPK 0
• CD40 0
• CSF1R 1
• JNK 0
• METTL3 0
• MMP-9 0
• PKM2 0
• SIRT1 0

2069 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DuoLipo-TNP: Dual-Responsive Liposome Platform for Selective Delivery of Triphosphate Nucleotide Prodrugs in Triple-Negative Breast Cancer

  Cardiff University· Cardiff, Egyesült Királyság· EU contribution 260 348 EUR· until 2029. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Mapping antigenic niches of tumor-infiltrating B cells in triple-negative breast cancer (MAP-BC)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 252 180 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Biomimetic MXene Nanoplatforms for Targeted Combination Therapy of Triple-Negative Breast Cancer (BioMIX)

  Latvijas Universitate· Riga, Lettország· EU contribution 1 147 740 EUR· until 2030. okt.· 12 countries

• European Commission (Horizon Europe) · HORIZON-EIC

  Next generation therapeutic vaccine for targeted cancer treatment (VacciNEXT)

  Basinnov Life Sciences Unipessoal Lda· Lisboa, Portugália· EU contribution 2 827 529 EUR· until 2029. szept.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Co-culture System with Microfluidics and Onboard Sensors for Breast Cancer study (CoSMOS-BC)

  Universidad del Pais Vasco/ Euskal Herriko Unibertsitatea· Leioa, Spanyolország· EU contribution 209 915 EUR· until 2028. aug.

  The disease is named only in the funder's project summary, not in the title.

5 of 24 running projects, newest first. Listed amounts together: 18,5 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

  NCT03979508· Mayo Clinic· Frissítve: 2026. nov. 2.

  “The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in first stage of study.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  PRO1107 in Patients With Advanced Solid Tumors

  NCT06171789· Genmab· Frissítve: 2026. okt. 29.

  “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

  NCT06568692· Processa Pharmaceuticals· Frissítve: 2026. okt. 6.

  “Business Reason”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

  NCT06959537· M.D. Anderson Cancer Center· Frissítve: 2026. okt. 5.

  “PI Request”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· UNICANCER· Frissítve: 2026. szept. 29.

  “The study was terminated prematurely due to insufficient patient recruitment.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

  NCT04638751· Persephone Biosciences· Frissítve: 2026. szept. 18.

  “Currently no funding to continue study.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

  NCT04251533· Novartis Pharmaceuticals· Frissítve: 2026. szept. 10.

  “The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

  NCT04315233· University of Utah· Frissítve: 2026. szept. 4.

  “No accrual in one year”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

  NCT05756166· Roswell Park Cancer Institute· Frissítve: 2026. aug. 31.

  “Funding ended”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

  NCT02993068· M.D. Anderson Cancer Center· Frissítve: 2026. aug. 26.

  “Accrual Limit”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

  NCT04052555· National Cancer Institute (NCI)· Forrás

• Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

  NCT07619534· National Cancer Institute (NCI)· Forrás

• Onvansertib + Paclitaxel In TNBC

  NCT05383196· Antonio Giordano, MD· Forrás

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Forrás

• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

  NCT05422794· National Cancer Institute (NCI)· Forrás

• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

  NCT03606967· National Cancer Institute (NCI)· Forrás

• Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

  NCT05111561· National Cancer Institute (NCI)· Forrás

• An international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.

  2025-523824-39-01· Medica Scientia Innovation Research S.L.· Forrás

• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

  NCT03742102· AstraZeneca· Forrás

• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

  NCT04491942· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 46
• Organoids 9
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 10
• Gene Expression Profiling 110
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 4
• Exome Sequencing 5
• Proteomics 32
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 49
• Liquid Biopsy 4
• Circulating Tumor DNA 16
• Xenograft Model Antitumor Assays 254
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 34
• Machine Learning 28
• Deep Learning 15
• Cohort Studies 21
• Genome-Wide Association Study 3

• Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.

  Cell Rep Med, 2026. aug.

• A Robust Protocol for the Establishment, Expansion, Bio-Banking, and Molecular Profiling of Triple-Negative Breast Cancer Organoids.

  Appl Immunohistochem Mol Morphol, 2026. júl.

• Overcoming immunotherapy resistance in triple-negative breast cancer: a critical review of mast cell plasticity, metabolic reprogramming, and organoid models.

  Front Immunol, 2026. máj.

• The Organoid Decade: Leveraging 3D Patient-Derived Organoids to Bridge the Translational Gap in Triple-Negative Breast Cancer: A Systematic Review.

  Cells, 2026. máj.

• A compatible gravity-driven organoid perfusion (GDOP) platform for drug screening with sensitivity and toxicity process evaluation.

  Commun Biol, 2026. ápr.

• High-throughput engineered tumor organoids reveal ROCK signaling as an immunotherapeutic target in triple-negative breast cancer.

  Cell Rep, 2026. febr.

• The effect of stiffness on cell behavior and drug resistance in patient-derived breast cancer organoids.

  Acta Biomater, 2025. dec.

• Selective HDAC6 inhibition by Mesinostat impairs tumor growth and stemness in triple-negative breast cancer.

  Pharmacol Res, 2025. dec.

• Drug screening reveals the mechanism of toyocamycin-induced apoptosis in triple-negative breast cancer organoids.

  Toxicol Appl Pharmacol, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.